TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Dysphagia/Aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the Ada WRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehensiveness of the Ada WRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gallstones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Speed of gait at preferred pace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cadence of gait at preferred pace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Length of gait at preferred pace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean anterior chamber cell/flare score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactile acuity - 2 point discrimination test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactile acuity - Absolute threshold detection test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge levels
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of the Collapsibility Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurement of the Distensibility Index of the inferior vena cava
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ratio of the maximum diameter of the IVC to the diameter of the Abdominal Aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Targeted lesion failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of death or lung transplant
Endpoint domain: Mortality/survival
Primary endpoint: Time to acute exacerbations and hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of requirement of interventions during hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Neck Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sternocleidomastoideus (SCM) myotonometric measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Trapezius myotonometric measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Biceps brachii myotonometric measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pectoralis Major (PM) myotonometric measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rectus abdominis (RA) myotonometric measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Need for endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequencies of abnormal sound waves in the pulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of sound waves in the pulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to VNS therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Weight in Pounds From Baseline to 16-week Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Losing 5 Percent or More of Weight From Baseline to 16-week Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SF-36 Physical Composite Score (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF-36 Mental Composite Score (MCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: initial directional error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial rate of learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative oxyhemoglobin concentration ([02Hb]) in the ventrolateral prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: relative oxyhemoglobin concentration ([02Hb]) in the dorsolateral prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of TAS-117
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severity of itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of NSBB (Propanolol) efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in subfoveal choroidal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of neoadjuvant Nivolumab in combination with HuMax
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral connectivity patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Magnesium percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of subjects with discontinuations due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with Treatment Related Adverse Events of Special Interest (TRAEs SI)
Endpoint domain: Adverse events/effects
Primary endpoint: epiglottis-skin thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nitric oxide (NO) plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelin 1 (ET-1) plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow mediated dilatation test result (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hematocrit evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of diagnostics obtained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Emotional Stroop
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Flanker Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Peri-implant soft tissue health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMT of varicella antibody in children aged 1-6 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT of varicella antibody in healthy people aged 0-59 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dose Limiting Toxicities (DLTs) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients reducing exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative Covid-19 test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance or Improvement of the most common clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stent Intragastric migration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Performance of robot-assisted radical prostatectomy (RARP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MOS generation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage of empyema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Psychological Outcomes Profile
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUCt of Irbesartan and Amlodipne High
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax Irbesartan and Amlodipne High
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of ocular surface staining (OSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day modified Rankin Scale (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Test-Retest Reliability of Hand Function Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience One or More AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinue Study Intervention Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants without Severe Vaso-occlusive Crises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Total body length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Height velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of QOL questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Joint Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of Skeletal survey by x-rays
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Active graph (bracelet)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wellness Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Geometrical accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiodensity accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of landmarks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of changes in valve settings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of PTG-300 in reducing elevated hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Evaluation of the mean size of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crying time in seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IBS Symptom Severity Scores (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine responses to mycobacterial antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physical activity scale for the elderly (PASE)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vascular function: Pulse wave velocity and Aortic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma lipid mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CRC-KPSS change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean signal to noise ratio of HP 13C-aKG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who reported treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Spleen volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MPN-SAF TSS 2.0
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postprandial P-glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of ZSP1603
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance participants alive and progression free (APF12)
Endpoint domain: Mortality/survival
Primary endpoint: AUCnic0-240
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral response (antibodies) to the anti-SARS-CoV-2 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of positive cases after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Cellular response (T lymphocytes and B lymphocytes) to the anti-SARS-CoV-2 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in global health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: LPR Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LPR Events
Endpoint domain: Adverse events/effects
Primary endpoint: free hemoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in fecal hemoglobin content (FHC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adherence to the TRE diet
Endpoint domain: Life impact
Endpoint subdomain: Dietary adherence
Primary endpoint: Rate of Progression of DB's
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utility of DB's
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Depression, anxiety, and stress scale (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Range of motion in the cervical region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache presence and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Daily data on gastrointestinal tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood results for valine, leucine, isoleucine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of the analyte in plasma at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe cases of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Change in Soleus MVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of pneumocephalus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Genital Tract Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Lactobacillus-dominant Vaginal Microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Vaginal Colonization of L. Crispatus CTV-05
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Vaginal Dysbiosis Indicated by a Nugent Score 4-10 on Vaginal Gram Stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Any Solicited Adverse Events (AEs) Through the Final Visit
Endpoint domain: Adverse events/effects
Primary endpoint: Functional success rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Range of motion of knee and ankle joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival after recurrence
Endpoint domain: Mortality/survival
Primary endpoint: occurrence of perioperative hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Transcutaneous partial pressure of oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of gingival pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in log-transformed UPCR at the 12-month visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in pain upon walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of colorectal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Impact on quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Compliance with drug therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complications and extraordinary recourse to health care
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and feasibility of device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasogastric tube feeding skill test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Confidence scale (C-scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Learning Self-Efficacy Scale (L-SES)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: quality of life using Kansas City Cardiomyopathy Questionnaire Summary Score (KCCQ-SC)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: N-terminal Pro B-type Natriuretic Peptide (NTproBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical outcomes of MAFLD vs. non-MAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in resting state electroencephalography (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in total sleep via Oura Ring
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Acute complication
Endpoint domain: Adverse events/effects
Primary endpoint: Subacute complication
Endpoint domain: Adverse events/effects
Primary endpoint: Leadless Pacemaker performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Edinburgh Visual Gait Score (EVGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPADI value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of the left ventricular deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of biopsy tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titers (GMTs) of antibodies against meningococcal serogroups A, C, W, and Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with Ab against meningococcal serogroups A, C, W, and Y above predefined thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine seroresponse against meningococcal serogroups A, C, W, and Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: musculoskeletal chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tongue Features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Abnormal Values in Targeted Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Abnormal Values in Clinical Laboratory Test Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of sealant's retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of DaRT seed placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety - Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Differential CSF proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stool Frequency Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Histologic Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative testing value
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of foot reflexology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of foot reflexology
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Physical activity level effect on sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity level effect on urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment proportion of CXCL13+PD1+ CD8 T cells in all CD8 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Edema redevelopment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes